Arxx Therapeutics
Develops a first-in-class monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
* | N/A | Merger | |
| Total Funding | 000k | ||
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads